TB CLIPS newsletter masthead: TB information in your hands, with lung and bacillus graphics.

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP - TB 코리아 소식

국내에는 소아 청소년 결핵환자가 거의 없지만, 15세 미만의 어린이와 청소년 환자는 전 세계적으로 결핵환자의 약 11%인 110만 명이 결핵에 걸립니다. 세계보건기구(WHO)는 소아(0-<10세) 및 청소년(10-19세 포함)의 결핵 치료 지침이 담긴 ‘operational handbook’을 발간하였습니다. Delamanid는 이 지침에서 모든 연령대의 어린이에게 처방할 것을 권고 받았으며, Tajikistan의 TB 아동 치료에 대한 Medecins Sans Frontieres의 특집기사에서 다른 신약들과 함께 찬사를 받았습니다.

The WHO publishes its ‘ operational handbook ’ with guidelines on how to treat TB in children (0-< 10 years) and teenagers (10-19 years, inclusive). Delamanid is specifically recommended for prescription in children of all ages.

Medecins Sans Frontieres welcomes this new WHO handbook, while noting that more than 60 per cent of children with TB remain undiagnosed, and testing for the disease in low-income countries faces challenges.

The WHO calls for an urgent investment of resources, support, care and information for the fight against TB.

The Global Fund (GF) called on everyone to ‘reignite’ the fight to end TB. GF Executive Director Peter Sands said: “If we fail to step up the fight against TB, we must accept that we are effectively abandoning the 2030 goal to end the disease as a public health threat.”

Stop TB Partnership calls for a fourfold increase in funding for the global TB response .

TB Alliance sounds the alarm that in 2020 the world saw the first increase in deaths from the disease since 2005, and a 15 per cent reduction in the number of people treated for drug-resistant TB.
Live demo of WHO’s End TB e-learning platform.
Date: 5 May, 2022; time: 1300-1500 CET
Connection details: https://who.zoom.us/j/95624138945;
passcode: Demo@202

World TB day 2022 campaign reached more than one billion people.

TB reach initiative seeks experts for proposal review committee.

The Lancet published a Series reviewing the effects of COVID-19 on global efforts to reduce the TB burden, identifying points of intersection between the two pandemics and highlighting new strategies for TB control.

Delamanid is praised in this feature from Medecins Sans Frontieres about treating children with TB in Tajikistan.

A comment , published in The Lancet Infectious Diseases, reflects on how to achieve global TB control targets through adapting COVID-19 program innovations to enhance access to integrated, patient-centred TB services.

Bedaquiline is cited in this thought piece by the increasingly high-profile author of ‘Phantom Plague: How Tuberculosis Shaped History’. The author, Vidya Krishnan, argues the poor are under-treated and the rich over-treated when it comes to health, and we face an ‘antibiotics apocalypse’.

The WHO sets out several reasons why TB transmission in Africa is increasing , including inadequate screening and testing, and the switching of limited resources to countering the Covid-19 pandemic.

An interview with Clinical Development Leader, Dr Alemnew Dagnew, of the Bill & Melinda Gates Foundation, Medical Research Institute, about their TB vaccine work.

A persistent cough may be TB, not Covid, warns a top UK public health expert.

In a study published in Cell Chemical Biology, researchers identified a novel target for TB 'host-directed therapy' and delivered a newly designed chemical compound with drug-like properties that could be used to treat the disease in combination with existing antibiotics.

According to a study published in PLOS Pathogens, the immune response mounted against TB in mice prevents them from developing COVID-19

According to a study published in Clinical Infectious Diseases, concomitant treatment with bedaquiline and delamanid was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant TB.

A study published in the American Journal of Respiratory and Critical Care Medicine, called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant TB.

In a study published in Aging, researchers found that the cells of humans and animals that have recovered from TB had prematurely aged up to 12 to 14 years. 'It’s possible that this premature cellular aging is one reason why survivors of TB have a higher risk of mortality, sometimes a three-fold higher.'